Press release
Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies| Zurex Pharma, Dr. Reddy's Laboratories, Botanix Pharma, Menarini Group Pharma, PolyPid and Others
Surgical Site Infection Market
The Surgical Site Infection market report also proffers an analysis of the current Surgical Site Infection treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
To know more about Surgical Site Infection Market Report. Click here @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr
Some of the vital takeaways of the Surgical Site Infection Market Research Report
• A slew of companies such as Zurex Pharma, Dr. Reddy's Laboratories Ltd., Botanix Pharma, Menarini Group Pharma, PolyPid, Destiny Pharma, and others are developing Surgical Site Infection therapies to influence treatment outlook.
• In Nov 2020, PolyPid Ltd. announced that D-PLEX100 received Breakthrough Therapy Designation from the US Food and Drug Administration to prevent Surgical Site Infections in patients undergoing elective colorectal surgery.
• The prophylactic therapy segment is XF-73 under development by Destiny Pharma with its antimicrobial "XF" drug platform. XF-73 was awarded QIDP status in October 2015.
• Presently the emerging therapies such as XF-73, D-PLEX100, DFA-02, BTX 1801, ZuraGard, and others are focused on treating or preventing Surgical Site Infection in either cardio or abdominal surgeries in the prophylactic segment, while Delafloxacin is used for the Surgical Site Infection treatment.
• Under the Surgical Site Infection treatment market, Delafloxacin by Menarini Group is the only upcoming therapy for a patient with incisional, superficial or deep, surgical site infection after cardiothoracic/related leg or abdominal surgery.
• Delafloxacin, under the name of Baxdela (fluoroquinolone antibacterial), received FDA approval for the Acute Bacterial Skin and Skin Structure Infections treatment, announced by Melinta Therapeutics in June 2017.
• Menarini Group and Melinta Therapeutics entered into a co-development and commercial agreement in 68 Countries for Delafloxacin in 2017.
• The future development of new modalities in Surgical Site Infection treatment and prophylaxis appears promising during the forecast period of 2021-2030. Of the emerging therapies, XF-73, D-PLEX100, BTX 1801, Delafloxacin, DFA-02, Zuragard, and others are expected to change the Surgical Site Infection market scenario in the upcoming years.
To know more facts about Surgical Site Infection Market and Epidemiology Report. Click here @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr
Surgical Site Infections (SSIs) are the most common nosocomial infection and frequently cause morbidity and mortality among patients of hospitals.
As per DelveInsight's research, the total Surgical Site Infection Incident cases in the 7MM were 1,323,491 cases in 2018. Moreover, it is observed that males and females are equally affected.
Surgical Site Infection Emerging Therapies Along with Key Players
1. XF-73: Destiny Pharma
2. D-PLEX100: PolyPid
3. Delafloxacin: Menarini Group Pharma
4. BTX 1801: Botanix Pharma
5. DFA-02: Dr Reddy's Laboratories Ltd.
6. Zuragard: Zurex Pharma
7. And several others.
To know more facts about Surgical Site Infection Pipeline Therapies. Click here @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr
Scope of the Surgical Site Infection Market Insight Report
1. Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
2. Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
3. Surgical Site Infection Markets Segmentation: By Geographies and By Surgical Site Infection Therapies (Historical and Forecasted, Current and Upcoming)
4. Dominant Market Companies investigating its candidates for Surgical Site Infection: Zurex Pharma, Dr. Reddy's Laboratories Ltd., Botanix Pharma, Menarini Group Pharma, PolyPid, Destiny Pharma, and several others.
5. Analysis: Comparative and conjoint analysis of emerging therapies.
6. Case Studies
7. KOL's Views
8. Analyst's View
Request for Sample Report: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Surgical Site Infection Key Insights
2. Surgical Site Infection Report Introduction
3. Surgical Site Infection Prophylactic Market Overview at a Glance
4. Surgical Site Infection Treatment Market Overview at a Glance
5. Surgical Site Infection Executive Summary
6. Surgical Site Infection Disease Background and Overview
7. Surgical Site Infection Epidemiology and Patient Population
7.1. The United States
7.2. EU5 Countries
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. The United Kingdom
7.3. Japan
8. Surgical Site Infection Treatment and Management
9. Surgical Site Infection Prevention
10. Organizations contributing towards Surgical Site Infection
11. Surgical Site Infection Patient Journey
12. Surgical Site Infection Case Report
13. Surgical Site Infection Emerging Therapies
13.1. XF-73: Destiny Pharma
13.2. D-PLEX100: PolyPid
13.3. Delafloxacin: Menarini Group Pharma
13.4. BTX 1801: Botanix Pharma
13.5. DFA-02: Dr. Reddy's Laboratories Ltd.
13.6. Zuragard: Zurex Pharma
14. 7MM Surgical Site Infection Market Analysis
14.1. The United States Surgical Site Infection Market Size
14.2. EU-5 Surgical Site Infection Market Size
14.2.1. Germany Market Size
14.2.2. France Market Size
14.2.3. Italy Market Size
14.2.4. Spain Market Size
14.2.5. The United Kingdom Market Size
14.3. Japan Surgical Site Infection Market Size
15. Surgical Site Infection Market Drivers
16. Surgical Site Infection Market Barriers
17. SWOT Analysis of Surgical Site Infection
18. Surgical Site Infection Unmet Needs
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Request for Detailed TOC @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies| Zurex Pharma, Dr. Reddy's Laboratories, Botanix Pharma, Menarini Group Pharma, PolyPid and Others here
News-ID: 2606099 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Infection
Growing Hospital-Acquired Infection Rates Boost Demand For Infection Prevention …
The Infection Prevention Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Infection Prevention Market?
In the past few years, there has been a consistent increase in the size of the infection prevention market. It is predicted that this market…
Prominent Infection Prevention Market Trend for 2025: Strategic Staffing Innovat …
What Are the Projected Growth and Market Size Trends for the Infection Prevention Market?
The infection prevention market is expected to grow from $43.4 billion in 2024 to $45.01 billion in 2025, reflecting a CAGR of 3.7%. Growth drivers include increasing awareness of healthcare-associated infections (HAIs), stringent regulatory guidelines, technological advancements, and globalization.
The Infection Prevention market is expected to grow to $52.2 billion by 2029 at a CAGR of 3.8%, driven…
Yeast Infection Treatment Market Report 2024 - Yeast Infection Treatment Market …
"The Business Research Company recently released a comprehensive report on the Global Yeast Infection Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The yeast infection…
Combating Infection: Nontuberculous Mycobacterial Infection Market Analysis 2024 …
The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.
The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few…
Infection Surveillance Solutions Market: Empowering Infection Prevention | BD, B …
Allied Market Research analysts have recently introduced a new research study titled "Infection Surveillance Solutions Market- Global Outlook and Forecast 2023-2030." The report offers detailed insights and highlights key players in the industry, including Atlas Medical Software, Becton, Dickinson and Company, Baxter International, GOJO Industries, Deb Group, RL Solutions, HyGreen, Wolters Kluwer, Premier, and Truven Health Analytics. This comprehensive study provides in-depth and clear analysis, encompassing market definitions, classifications, manufacturing…
Infection Prevention & Control Market 2026: Product Overview and Scope of Infect …
Infection Prevention & Control Market Research Report and Forecast to 2019-2026 Report provide an extensive research on the fast-evolving Infection Prevention & Control Market. It also gives competitive landscape of the leading companies with regional and Global analysis of the market till 2026.
The report mainly studies the size, recent trends and development status of the Infection Prevention & Control market, as well as investment opportunities, government policy, market dynamics (drivers,…
